Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 16/20 | 0.64 |
| ▸ | PGR | P06401 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | FPR3 | P25089 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 1/20 | 0.60 |
| ▸ | GPR183 | P32249 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | P2RY13 | Q9BPV8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15859655 | 1.00 | P2RY12 (0.64) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL15859674 | 1.00 | P2RY12 (0.64) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL15846303 | 1.00 | P2RY12 (0.64) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL15859666 | 1.00 | P2RY12 (0.64) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL16800343 | 1.00 | P2RY12 (0.64) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL16800309 | 0.94 | P2RY12 (0.57) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL15057950 | 0.91 | P2RY12 (0.65) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL16800331 | 0.91 | P2RY12 (0.54) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL29351640 | 0.89 | P2RY12 (0.65) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL17665995 | 0.89 | P2RY12 (0.65) | P2RY12PGRADORA3CHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023223335-A1 | A METHOD FOR PREPARING (1S)-2-CHLORO-1-(3,4-DIFLUOROPHENYL) ETHANOL | AARTI PHARMALABS LIMITED (IN) | 2023-11-23 | — | — | WO | disclosed |
| EP-2794575-B1 | SYNTHESIS OF TRIAZOLOPYRIMIDINE COMPOUNDS | LEK PHARMACEUTICALS (SI) | 2018-12-05 | — | — | EP | disclosed |
| EP-2985286-B1 | MIDBODY OF TICAGRELOR AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR TICAGRELOR | JIANGSU HENGRUI MEDICINE CO (CN) | 2017-10-11 | — | — | EP | disclosed |
| US-9359366-B2 | Intermediate of Ticagrelor and preparation method therefor, and preparation method for Ticagrelor | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9359366-B2 | Intermediate of Ticagrelor and preparation method therefor, and preparation method for Ticagrelor | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9278972-B2 | Synthesis of triazolopyrimidine compounds | LEK PHARMACEUTICALS D.D. (SI) | 2016-03-08 | — | — | US | disclosed |
| US-9278972-B2 | Synthesis of triazolopyrimidine compounds | LEK PHARMACEUTICALS D.D. (SI) | 2016-03-08 | — | — | US | disclosed |
| US-9278972-B2 | Synthesis of triazolopyrimidine compounds | LEK PHARMACEUTICALS D.D. (SI) | 2016-03-08 | — | — | US | disclosed |
| EP-2985286-A1 | MIDBODY OF TICAGRELOR AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR TICAGRELOR | Jiangsu Hengrui Medicine Co. Ltd. (CN) | 2016-02-17 | — | — | EP | disclosed |
| US-9233966-B2 | Preparation of ticagrelor | DR. REDDY'S LABORATORIES LIMITED (IN) | 2016-01-12 | — | — | US | disclosed |
| US-9056838-B2 | Intermediates and processes for preparing Ticagrelor | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-06-16 | — | — | US | disclosed |
| US-20150073146-A1 | PREPARATION OF TICAGRELOR | DR. REDDY'S LABORATORIES LIMITED (IN) | 2015-03-12 | — | — | US | disclosed |
| EP-2834247-A2 | PREPARATION OF TICAGRELOR | Dr. Reddy's Laboratories Ltd. (IN) | 2015-02-11 | — | — | EP | disclosed |
| US-20140371449-A1 | Synthesis of Triazolopyrimidine Compounds | LEK PHARMACEUTICALS D.D. (SI) | 2014-12-18 | — | — | US | disclosed |
| US-20140371449-A1 | Synthesis of Triazolopyrimidine Compounds | LEK PHARMACEUTICALS D.D. (SI) | 2014-12-18 | — | — | US | disclosed |
| US-20140371449-A1 | Synthesis of Triazolopyrimidine Compounds | LEK PHARMACEUTICALS D.D. (SI) | 2014-12-18 | — | — | US | disclosed |
| WO-2013150495-A2 | PREPARATION OF TICAGRELOR | DR. REDDY'S LABORATORIES LIMITED (IN) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013092900-A1 | SYNTHESIS OF TRIAZOLOPYRIMIDINE COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2013-06-27 | — | — | WO | disclosed |
| EP-2607355-A1 | Synthesis of triazolopyrimidine compounds | LEK Pharmaceuticals d.d. (SI) | 2013-06-26 | — | — | EP | disclosed |
| EP-2607355-A1 | Synthesis of triazolopyrimidine compounds | LEK Pharmaceuticals d.d. (SI) | 2013-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150073146-A1 | PREPARATION OF TICAGRELOR | CYP3A4, CYP2C19, TBXAS1 | P2RY12 65/4885PGR 752/4885ADORA3 135/4885 |
| US-20140371449-A1 | Synthesis of Triazolopyrimidine Compounds | TBXAS1, TYMS, FDPS | P2RY12 90/4885PGR 2343/4885ADORA3 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.